Subcutaneous Bortezomib in Multiple Myeloma Patients Induces
Similar Therapeutic Response Rates as Intravenous Application
But It Does Not Reduce the Incidence of Peripheral Neuropathy

J 2015

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy

MINARIK, Jiri, Petr PAVLICEK, Luděk POUR, Tomas PIKA, Vladimir MAISNAR et. al.

Základní údaje

Originální název

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy

Autoři

MINARIK, Jiri (203 Česká republika), Petr PAVLICEK (203 Česká republika), Luděk POUR (203 Česká republika, garant, domácí), Tomas PIKA (203 Česká republika), Vladimir MAISNAR (203 Česká republika), Ivan SPICKA (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Marta KREJČÍ (203 Česká republika, domácí), Jaroslav BACOVSKY (203 Česká republika), Jakub RADOCHA (203 Česká republika), Jan STRAUB (203 Česká republika), Petr KESSLER (203 Česká republika), Marek WROBEL (203 Česká republika), Lenka WALTEROVA (203 Česká republika), Michal SYKORA (203 Česká republika), Jarmila OBERNAUEROVA (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Evzen GREGORA (203 Česká republika), Dagmar ADAMOVA (203 Česká republika), Jaromir GUMULEC (203 Česká republika), Zdeněk ADAM (203 Česká republika, domácí), Vlastimil SCUDLA (203 Česká republika) a Roman HAJEK (203 Česká republika)

Vydání

PLOS ONE, San Francisco, Public Library Science, 2015, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.057

Kód RIV

RIV/00216224:14110/15:00082780

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1371/journal.pone.0123866

UT WoS

000353014700049

Klíčová slova anglicky

INITIAL TREATMENT; PHASE-III; IMPACT; REVERSIBILITY; PREDNISONE; MELPHALAN; SURVIVAL; EFFICACY; TRIAL

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 6. 2015 14:33, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Objective Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) patients treated using either intravenous (IV) or subcutaneous (SC) route of administration. Patients and methods During January 2012 through December 2013, we performed a retrospective analysis of 446 patients with MM treated with bortezomib-based regimens (either once weekly – 63% or twice weekly – 27%) in both, the first line setting, and in relapse, with separate analysis of patients undergoing autologous stem cell transplantation. We assessed the response rates and toxicity profiles in both, IV and SC route of bortezomib administration. Results The response rates in both IV and SC arm were similar with overall response rate 71.7% vs 70.7%, complete remissions in 13.9%vs 8.6%, very good partial remissions in 30.8% vs 34.5% and partial remissions in 27% vs 27.6%. The most frequent grade 3 toxicities were anemia, thrombocytopenia and neutropenia, with no significant differences between IV and SC group. There were no significant differences in the rate of peripheral neuropathy (PN). PN of any grade was present in 48% in the IV arm and in 41% in the SC arm. PN grade 2 was present in 20% vs 18% and PN grade 3 was present in 6% vs 4%. Conclusions We conclude that subcutaneous application of bortezomib has similar therapeutic outcomes and toxicity profile as intravenous route of application. In our cohort there was no difference in the incidence of PN, suggesting that PN is dose dependent and might be reduced by lower intensity schemes rather than by the route of administration.

Návaznosti

MSM0021622434, záměr

Název: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Citovat

MINARIK, Jiri, Petr PAVLICEK, Luděk POUR, Tomas PIKA, Vladimir MAISNAR, Ivan SPICKA, Jiří JARKOVSKÝ, Marta KREJČÍ, Jaroslav BACOVSKY, Jakub RADOCHA, Jan STRAUB, Petr KESSLER, Marek WROBEL, Lenka WALTEROVA, Michal SYKORA, Jarmila OBERNAUEROVA, Lucie BROŽOVÁ, Evzen GREGORA, Dagmar ADAMOVA, Jaromir GUMULEC, Zdeněk ADAM, Vlastimil SCUDLA a Roman HAJEK. Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. PLOS ONE. San Francisco: Public Library Science, 2015, roč. 10, č. 4, s. "e0123866-1"-"e0123866-10", 10 s. ISSN 1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0123866.

@article{1298671,
   author = {Minarik, Jiri and Pavlicek, Petr and Pour, Luděk and Pika, Tomas and Maisnar, Vladimir and Spicka, Ivan and Jarkovský, Jiří and Krejčí, Marta and Bacovsky, Jaroslav and Radocha, Jakub and Straub, Jan and Kessler, Petr and Wrobel, Marek and Walterova, Lenka and Sykora, Michal and Obernauerova, Jarmila and Brožová, Lucie and Gregora, Evzen and Adamova, Dagmar and Gumulec, Jaromir and Adam, Zdeněk and Scudla, Vlastimil and Hajek, Roman},
   article_location = {San Francisco},
   article_number = {4},
   doi = {http://dx.doi.org/10.1371/journal.pone.0123866},
   keywords = {INITIAL TREATMENT; PHASE-III; IMPACT; REVERSIBILITY; PREDNISONE; MELPHALAN; SURVIVAL; EFFICACY; TRIAL},
   language = {eng},
   issn = {1932-6203},
   journal = {PLOS ONE},
   title = {Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy},
   volume = {10},
   year = {2015}
}

TY  - JOUR
ID  - 1298671
AU  - Minarik, Jiri - Pavlicek, Petr - Pour, Luděk - Pika, Tomas - Maisnar, Vladimir - Spicka, Ivan - Jarkovský, Jiří - Krejčí, Marta - Bacovsky, Jaroslav - Radocha, Jakub - Straub, Jan - Kessler, Petr - Wrobel, Marek - Walterova, Lenka - Sykora, Michal - Obernauerova, Jarmila - Brožová, Lucie - Gregora, Evzen - Adamova, Dagmar - Gumulec, Jaromir - Adam, Zdeněk - Scudla, Vlastimil - Hajek, Roman
PY  - 2015
TI  - Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
JF  - PLOS ONE
VL  - 10
IS  - 4
SP  - "e0123866-1"-"e0123866-10"
EP  - "e0123866-1"-"e0123866-10"
PB  - Public Library Science
SN  - 19326203
KW  - INITIAL TREATMENT
KW  - PHASE-III
KW  - IMPACT
KW  - REVERSIBILITY
KW  - PREDNISONE
KW  - MELPHALAN
KW  - SURVIVAL
KW  - EFFICACY
KW  - TRIAL
N2  - Objective Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) patients treated using either intravenous (IV) or subcutaneous (SC) route of administration. Patients and methods During January 2012 through December 2013, we performed a retrospective analysis of 446 patients with MM treated with bortezomib-based regimens (either once weekly – 63% or twice weekly – 27%) in both, the first line setting, and in relapse, with separate analysis of patients undergoing autologous stem cell transplantation. We assessed the response rates and toxicity profiles in both, IV and SC route of bortezomib administration. Results The response rates in both IV and SC arm were similar with overall response rate 71.7% vs 70.7%, complete remissions in 13.9%vs 8.6%, very good partial remissions in 30.8% vs 34.5% and partial remissions in 27% vs 27.6%. The most frequent grade 3 toxicities were anemia, thrombocytopenia and neutropenia, with no significant differences between IV and SC group. There were no significant differences in the rate of peripheral neuropathy (PN). PN of any grade was present in 48% in the IV arm and in 41% in the SC arm. PN grade 2 was present in 20% vs 18% and PN grade 3 was present in 6% vs 4%. Conclusions We conclude that subcutaneous application of bortezomib has similar therapeutic outcomes and toxicity profile as intravenous route of application. In our cohort there was no difference in the incidence of PN, suggesting that PN is dose dependent and might be reduced by lower intensity schemes rather than by the route of administration.
ER  -

MINARIK, Jiri, Petr PAVLICEK, Luděk POUR, Tomas PIKA, Vladimir MAISNAR, Ivan SPICKA, Jiří JARKOVSKÝ, Marta KREJČÍ, Jaroslav BACOVSKY, Jakub RADOCHA, Jan STRAUB, Petr KESSLER, Marek WROBEL, Lenka WALTEROVA, Michal SYKORA, Jarmila OBERNAUEROVA, Lucie BROŽOVÁ, Evzen GREGORA, Dagmar ADAMOVA, Jaromir GUMULEC, Zdeněk ADAM, Vlastimil SCUDLA a Roman HAJEK. Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. \textit{PLOS ONE}. San Francisco: Public Library Science, 2015, roč.~10, č.~4, s.~''e0123866-1''-''e0123866-10'', 10 s. ISSN~1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0123866.

Podrobný výpis o publikaci